CapsoVision (CV) Competitors $4.90 -0.01 (-0.20%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock CV vs. BBNX, EMBC, AXGN, CLPT, SIBN, BVS, ZIMV, BFLY, AVNS, and CBLLShould you be buying CapsoVision stock or one of its competitors? The main competitors of CapsoVision include Beta Bionics (BBNX), Embecta (EMBC), AxoGen (AXGN), ClearPoint Neuro (CLPT), SiBone (SIBN), Bioventus (BVS), ZimVie (ZIMV), Butterfly Network (BFLY), Avanos Medical (AVNS), and CeriBell (CBLL). These companies are all part of the "medical equipment" industry. CapsoVision vs. Its Competitors Beta Bionics Embecta AxoGen ClearPoint Neuro SiBone Bioventus ZimVie Butterfly Network Avanos Medical CeriBell Beta Bionics (NASDAQ:BBNX) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment. Does the media refer more to BBNX or CV? In the previous week, Beta Bionics had 7 more articles in the media than CapsoVision. MarketBeat recorded 10 mentions for Beta Bionics and 3 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.94 beat Beta Bionics' score of 0.51 indicating that CapsoVision is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CapsoVision 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has better earnings and valuation, BBNX or CV? CapsoVision has lower revenue, but higher earnings than Beta Bionics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeta Bionics$65.12M13.98-$54.76MN/AN/ACapsoVisionN/AN/AN/AN/AN/A Is BBNX or CV more profitable? Company Net Margins Return on Equity Return on Assets Beta BionicsN/A N/A N/A CapsoVision N/A N/A N/A Do analysts prefer BBNX or CV? Beta Bionics presently has a consensus price target of $24.56, suggesting a potential upside of 17.21%. CapsoVision has a consensus price target of $5.50, suggesting a potential upside of 12.24%. Given Beta Bionics' stronger consensus rating and higher probable upside, analysts clearly believe Beta Bionics is more favorable than CapsoVision.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beta Bionics 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.69CapsoVision 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 SummaryBeta Bionics beats CapsoVision on 5 of the 6 factors compared between the two stocks. Get CapsoVision News Delivered to You Automatically Sign up to receive the latest news and ratings for CV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CV vs. The Competition Export to ExcelMetricCapsoVisionSurgical, Medical, And Dental Instruments And Supplies IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$229.66M$181.26M$2.54B$10.68BDividend YieldN/AN/A2.50%4.82%P/E RatioN/A1.9921.9229.71Price / SalesN/A4.67113.09132.28Price / CashN/A3.9543.6761.44Price / BookN/A1.5533.126.60Net IncomeN/A-$51.31M$6.87M$276.82M7 Day Performance1.24%-0.05%1.18%2.07%1 Month Performance8.41%-2.81%0.62%2.62%1 Year PerformanceN/A367.04%93.35%32.86% CapsoVision Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVCapsoVisionN/A$4.90-0.2%$5.50+12.2%N/A$229.66MN/A0.0090News CoverageAnalyst ForecastBBNXBeta Bionics2.6864 of 5 stars$20.02-3.0%$24.44+22.1%N/A$870.27M$65.12M0.00294Analyst ForecastShort Interest ↑EMBCEmbecta4.7283 of 5 stars$13.56-0.9%$19.00+40.1%+0.9%$793.06M$1.12B9.482,100Positive NewsAnalyst ForecastAXGNAxoGen3.5324 of 5 stars$16.59-0.9%$25.75+55.2%+37.6%$763.36M$203.27M-165.88450Upcoming EarningsAnalyst ForecastCLPTClearPoint Neuro1.0456 of 5 stars$25.38+0.4%$19.67-22.5%+105.6%$721.34M$31.39M-31.33110Analyst ForecastSIBNSiBone3.4311 of 5 stars$14.74-2.4%$23.00+56.0%+21.1%$635.90M$185.26M-26.32350BVSBioventus2.5587 of 5 stars$6.66-3.2%$13.75+106.5%-47.6%$550.64M$564.14M-10.921,200ZIMVZimVie0.6884 of 5 stars$18.99flat$17.75-6.5%+34.3%$535.73M$449.75M-27.131,770Upcoming EarningsHigh Trading VolumeBFLYButterfly Network2.7322 of 5 stars$2.12-5.5%$3.00+41.8%+34.0%$533.69M$82.06M-7.56460Upcoming EarningsAnalyst ForecastGap UpAVNSAvanos Medical2.5624 of 5 stars$11.44-0.3%N/A-47.3%$530.84M$692.50M-1.142,227News CoverageUpcoming EarningsCBLLCeriBell2.5553 of 5 stars$12.71-2.2%$32.14+152.9%N/A$466M$65.44M-4.25N/APositive NewsAnalyst Forecast Related Companies and Tools Related Companies BBNX Alternatives EMBC Alternatives AXGN Alternatives CLPT Alternatives SIBN Alternatives BVS Alternatives ZIMV Alternatives BFLY Alternatives AVNS Alternatives CBLL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CV) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredBitcoin is dead?Bitcoin’s historic run may be ending — and Weiss Ratings’ Juan Villaverde, who’s nailed every major crypto bul...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CapsoVision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CapsoVision With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.